Design Therapeutics (DSGN) Total Non-Current Liabilities (2020 - 2021)
Design Therapeutics (DSGN) posted quarterly Total Non-Current Liabilities of $8.8 million for Q3 2021, up 157.8% on a QoQ basis from $3.4 million in Q2 2021.
Powered by 
Analysis
Design Therapeutics (DSGN) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends
Design Therapeutics has reported Total Non-Current Liabilities for 2 years, with the latest figure at $8.8 million in Q3 2021.
- Total Non-Current Liabilities for Q3 2021 came in at $8.8 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2021 was $8.8 million (changed N/A YoY), and the FY2020 annual result was $2.3 million, changed N/A from the prior year.
- Total Non-Current Liabilities advanced to $8.8 million in Q3 2021, from $3.4 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $8.8 million in Q3 2021 and troughed at $2.3 million in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Design Therapeutics | 945.71 Mn | 738.31 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 8.78 Mn |
| Jun 30, 2021 | 3.41 Mn |
| Mar 31, 2021 | 3.71 Mn |
| Dec 31, 2020 | 2.33 Mn |